Skip to content

Evaluation of a Cognitive Behavioral Smoking Reduction Program

Das Verhaltenstherapeutische Therapiemanual Smoke_less Zur Reduktion Des Tabakkonsums: Eine Evaluationsstudie Mit Ambulanten Patienten

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02337400
Enrollment
155
Registered
2015-01-13
Start date
2015-01-31
Completion date
2016-04-30
Last updated
2016-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Reduction

Brief summary

The aim of this study is to evaluate a new cognitive behavioral smoking reduction program for ambulant patients in a three-armed study design. Study participants will be randomized to one of the following three study groups: experimental group: 5-week lasting cognitive behavioral reduction program (smoke\_less); active comparator: 15 minutes counseling interview; waiting group: no intervention. The three follow-up measures take place after the reduction program in week 6, 17 an 29. After the finalisation of the last follow-up, participants from the active comparator and waiting group get the chance to take part at the smoking reduction program at no charge.

Interventions

BEHAVIORALCognitive behavioral smoking reduction program Smoke_less

Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls

BEHAVIORAL15 minute counseling interview

Sponsors

Ludwig-Maximilians - University of Munich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* 18-70 years * Result Fagerström-Test \>= 3 * Consumption of at least 10 Cig./day * carbon monoxide \>= 8 ppm * Wish, to reduce smoking but no intention to stop smoking within the next 4 weeks * Agreement, to resign to nicotine replacement therapy, other therapies for smoking reduction, e-cigarettes or non-smoking tobacco products during study time

Exclusion criteria

* severe psychiatric disorder * severe neurologic disease * alcohol, drug or medication abuse (acute or in anamnesis) * severe cardiovascular disease * severe cancer disease * severe internal disease * Consumption of psychopharmacological medication * acute suicidal tendency * pregnancy or lactation * consumption of medication therapy for smoking reduction in the last 3 month

Design outcomes

Primary

MeasureTime frame
Change from baseline in number of smoked cigarettes/day at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in percentage of carbon monoxide in exhalation air at 6, 17 and 29 weeks6, 17 and 29 weeks

Secondary

MeasureTime frame
Change from baseline in Readiness to Change Questionnaire at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in Process of Change Questionnaire at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in Decisional Balance Questionnaire at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in Fagerström Test for Nicotine Dependence at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in knowledge and skills scale about smoking reduction at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in stress scale at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in health satisfaction satisfaction scale at 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in Self-Efficacy scale for smokers 6, 17 and 29 weeks6, 17 and 29 weeks
Change from baseline in Questionnaire of Smoking Urges at 6, 17 and 29 weeks6, 17 and 29 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026